Making Sense of the Novo Nordisk-Walmart Partnership to Sell Some Discounted Insulin Analogues

On June 29, 2021, Walmart Inc. and the American business unit of Novo Nordisk A/S (which is based just outside of Princeton, New Jersey known as Novo Nordisk Inc.) dropped what was intended to be a news bombshell coming just as the ADA Scientific Sessions was coming to a close. In fact, the insulin makers had hardly any big news coming from the ADA Scientific Sessions themselves this year (in fact, Novo Nordiskacquired a UK-based company known as Ziylo in 2018 to use its technology to try and develop glucose-responsive insulin, but it still has a long while before it is ready for commercialization ... if ever), because most have shifted R&D towards GLP-1 inhibitors for T2D, and regularly get assaulted over runaway prices, so why not make some headlines by doing something intended to capture press attention of a captive audience?!In essence, the pharmacies in Walmart ' s retail stores will start selling a version of Novo Nordisk ' s slightly older (and now out-of-patent, more on that in a minute) rapid-acting insulin analogue branded as Novolog which they will call Relion Novolog in the U.S. for $72.88 per vial and the company ' s 5-pack of insulin pens branded as FlexPens for $85.88. See the press release from Walmart HEREhttps://www.businesswire.com/news/home/20210629005683/en/Walmart-Revolutionizes-Insulin-Access-Affordability-for-Patients-With-Diabetes-With-the-Launch-of-the-First-and-Only-Private-Brand-Analog-Insulin for details). In Walmart ' s press releas...
Source: Scott's Web Log - Category: Endocrinology Tags: Aspart Novo Nordisk Novolog Walmart Source Type: blogs